Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UK-369,003 modified-release versus placebo in men with LUTS
NL-OMON30658Phase 2Active, not recruiting
- Sponsor
- Pfizer
- Start
- May 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of gisadenafil in benign prostatic hyperplasia (BPH) and Micturition disorder (2 arms), sponsored by Pfizer. Primary endpoints: PdetQmax, Qmax and 10 more. Started May 2007; status: active, not recruiting.
02
Drugs
gisadenafil
03
Conditions
benign prostatic hyperplasia (BPH)Micturition disorder
Beyond the preview
Go deeper on NL-OMON30658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON30658.